Greenleaf Trust Purchases 173 Shares of Hologic, Inc. $HOLX

Greenleaf Trust raised its position in Hologic, Inc. (NASDAQ:HOLX) by 5.1% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 3,579 shares of the medical equipment provider’s stock after buying an additional 173 shares during the period. Greenleaf Trust’s holdings in Hologic were worth $233,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of HOLX. Farther Finance Advisors LLC boosted its position in shares of Hologic by 22.3% in the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider’s stock worth $113,000 after purchasing an additional 335 shares during the last quarter. United Services Automobile Association bought a new position in shares of Hologic in the 1st quarter worth $347,000. SG Americas Securities LLC boosted its position in shares of Hologic by 116.6% in the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider’s stock worth $594,000 after purchasing an additional 5,172 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Hologic in the 1st quarter worth $641,000. Finally, Cambridge Investment Research Advisors Inc. boosted its position in shares of Hologic by 1.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider’s stock worth $1,980,000 after purchasing an additional 528 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hologic Price Performance

NASDAQ:HOLX opened at $68.22 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The stock’s 50-day simple moving average is $66.97 and its 200 day simple moving average is $63.09. The company has a market cap of $15.17 billion, a P/E ratio of 28.31, a P/E/G ratio of 2.34 and a beta of 0.63. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Royal Bank Of Canada upgraded Hologic from a “sector perform” rating to an “outperform” rating and raised their price target for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Argus raised their price target on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Morgan Stanley raised their price target on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. Evercore ISI raised their price target on Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 8th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Hologic in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $79.38.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.